Jul. 24 at 12:03 PM
$PNGAF The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV
The Precision Peptide Company Inc. applauds today's vote by the U.S. Food and Drug Administration's ("FDA") Pharmacy Compounding Advisory Committee, which recommended that BPC-157 and KPV be considered for inclusion on the FDA's 503A Bulks List. While the recommendation is advisory and subject to final FDA review, the Company believes it represents a positive step toward improving patient access to quality-focused, professionally compounded peptide therapies: https://x.com/PrecisionPepCo/status/2080613925570167292
$HIMS $ENHA
